Chronic Lymphocytic Leukemia (CLL) Clinical Trials


Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Conditions:   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention:   Drug: Ibrutinib
Sponsors:   M.D. Anderson Cancer Center;   Pharmacyclics LLC.
Not yet recruiting - verified June 2017

Learn More

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions:   CLL;   SLL
Interventions:   Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Pembrolizumab
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified June 23, 2017

Learn More

Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies

Conditions:   Lymphoma, B-Cell;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma
Intervention:   Drug: ARQ 531
Sponsor:   ArQule
Recruiting - verified June 2017

Learn More

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Conditions:   Aggressive Non-Hodgkin Lymphoma;   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160;   Other: Pharmacological Study
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Not yet recruiting - verified December 2016

Learn More

Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Condition:   Leukemia
Interventions:   Drug: Rituximab;   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total body irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: G-CSF
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified June 2017

Learn More

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
Sponsor:   TG Therapeutics, Inc.
Recruiting - verified July 2017

Learn More

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Condition:   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions:   Drug: BI 836826;   Drug: Ibrutinib
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2017

Learn More

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017

Learn More

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Triple-Negative Breast Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: ROR1 CAR-specific Autologous T-Lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified June 2017

Learn More

Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients

Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: NiCord®;   Other: Cord Blood Unit
Sponsor:   Gamida Cell ltd
Recruiting - verified June 2017

Learn More

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Conditions:   Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention:   Drug: ADCT-402
Sponsor:   ADC Therapeutics SARL
Recruiting - verified June 2017

Learn More

Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Conditions:   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   CD19 Positive;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions:   Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Conditions:   CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Interventions:   Drug: Ibrutinib;   Drug: Fludarabine
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 6, 2017

Learn More

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Conditions:   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Nodal Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Splenic Marginal Zone Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Nodal Marginal Zone Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Refractory Splenic Marginal Zone Lymphoma;   Richter Syndrome;   Waldenstrom Macroglobulinemia
Interventions:   Drug: Ibrutinib;   Drug: Idelalisib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)

Condition:   Leukemia
Interventions:   Drug: Bosutinib;   Drug: Inotuzumab Ozogamicin;   Behavioral: Phone Call
Sponsors:   M.D. Anderson Cancer Center;   Pfizer
Recruiting - verified June 2017

Learn More

1-15 of 34
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.